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Understanding the fetal hepatic niche is essential
for optimizing the generation of functional hepato-
cyte-like cells (hepatic cells) from human embryonic
stem cells (hESCs). Here, we show that KDR
(VEGFR2/FLK-1), previously assumed to be mostly
restricted to mesodermal lineages, marks a hESC-
derived hepatic progenitor. hESC-derived endoderm
cells do not express KDRbut, when cultured inmedia
supporting hepatic differentiation, generate KDR+
hepatic progenitors and KDR hepatic cells. KDR+
progenitors require active KDR signaling both to
instruct their own differentiation into hepatic cells
and to non-cell-autonomously support the functional
maturation of cocultured KDR hepatic cells. Anal-
ysis of human fetal livers suggests that similar pro-
genitors are present in human livers. Lineage tracing
in mice provides in vivo evidence of a KDR+ hepatic
progenitor for fetal hepatoblasts, adult hepatocytes,
and adult cholangiocytes. Altogether, our findings
reveal that KDR is a conserved marker for endo-
derm-derived hepatic progenitors and a functional
receptor instructing early liver development.
INTRODUCTION
Liver disease affects millions of people worldwide. Hepatocyte
transplantation is considered a potential treatment for liver dis-
eases and a bridge for patients awaiting liver transplantation,
but its application has been hampered by a limited supply of748 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.hepatocytes. Human embryonic stem cells (hESCs) established
from early embryos or induced pluripotent stem cells (iPSCs)
derived from somatic adult cells are pluripotent and could
constitute an unlimited source of hepatocytes for cell replace-
ment therapy (Takahashi et al., 2007; Thomson et al., 1998).
Even though prior studies have established protocols to effi-
ciently generate in vitro hepatocyte–like (hepatic) cells from
hESCs (Agarwal et al., 2008; Cai et al., 2007; Duan et al., 2010;
Hay et al., 2008; Touboul et al., 2010) or hiPSCs (Hannan et al.,
2013; Si-Tayeb et al., 2010b; Sullivan et al., 2010), hepatic cells
remain mostly inefficient at repopulating diseased livers in vivo,
making a readout of their functional in vivo properties chal-
lenging. Although underlying mechanisms for the poor repopu-
lating ability of hESC-derived hepatic cells remain unknown,
recent studies have exploited the well-documented ability of
the hepatitis C virus (HCV) to specifically infect functional hepa-
tocytes, and this has demonstrated the functionality of human
pluripotent stem cell-derived hepatic cells (Roelandt et al.,
2012; Schwartz et al., 2012; Wu et al., 2012; Yoshida et al.,
2011). Thus, the translational potential of human pluripotent
stem cell-derived hepatic cells is already becoming a reality
through the development of model systems for studying the
host-viral interaction in HCV pathogenesis. Better insight into
how various components of the hepatic niche interact will there-
fore have a substantial clinical impact for both organ regenera-
tion and disease-modeling applications.
Liver organogenesis involves complex cell-cell interactions
occurring in early development. In the mouse, the septum trans-
versum and cardiac mesoderm secrete bone morphogenetic
proteins (BMPs) and fibroblast growth factors (FGFs) to instruct
the adjacent ventral endoderm to become hepatic endoderm (Si-
Tayeb et al., 2010a). Studies in Kdr null embryos demonstrated
that endothelial cells are required for the promotion of liver
morphogenesis prior to the formation of functional blood vessels
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entiation cocultures revealed that endothelial cells, through
regulation of Wnt and Notch pathways, also function to support
hepatic specification of the endoderm (Han et al., 2011). Consid-
ering the scarcity of early human fetal tissues, hESCs provide a
powerful in vitro model of early human developmental pro-
cesses. In this study, we find that KDR-expressing endothelial
cells coemerge with hepatic cells during hepatic differentiation
of hESCs. Although KDRexpression was thought to be restricted
tomesodermal derivatives (Ema et al., 2006; Holmes et al., 2007)
as well as to a subset of ectodermal-derived neurons (Sondell
and Kanje, 2001), to our surprise, we found that a distinct popu-
lation of hepatic progenitor cells characterized by KDR expres-
sion arises concurrently with hepatic cells. Our data also provide
evidence for the presence of KDR+ hepatic progenitors in devel-
opingmouse and human livers, supporting the concept that KDR
also marks an endoderm derivative.
RESULTS
Concomitant Development of KDR–CD31– Hepatic
Cells, KDR+CD31– Prehepatic Cells, and KDR+CD31+
Endothelial Cells in hESC-Derived Hepatic Cultures
For generation of hESC-derived hepatic cells, the endoderm
program was induced upon embryoid body (EB) formation using
Activin A (Figure 1A). Endoderm induction was very robust as
assessed by the high percentage of cells expressing CXCR4
and cKIT (Figure 1B, up to 95% CXCR4+cKIT+ cells at day 5),
two markers reflecting the development of endoderm in mouse
and human ESC differentiation cultures (D’Amour et al., 2005;
Gouon-Evans et al., 2006). To test whether the day 5 CXCR4+
cKIT+ endoderm-enriched cells were devoid of mesendoderm
cells, whose bipotentiality could give rise to endoderm and
mesoderm cells, we examined via flow cytometry in EBs expres-
sion of PDGFRa, which has been commonly used to mark mes-
endoderm cells emerging from mouse or human ESC cultures
(Kopper and Benvenisty, 2012; Tada et al., 2005) (Figure 1B).
These data revealed that at day 4 the vast majority of cells in
EBs (90.9% ± 9.3%) homogenously expressed PDGFRa,
whereas at day 5 (when cells were purified for CXCR4 and
cKIT expression) PDGFRa was dramatically downregulated
(0.38% ± 0.18%). These data demonstrate that the day 5
CXCR4+cKIT+ population that we propose is enriched for
endoderm cells is staged beyond the point of mesendoderm
development. A very small percentage of a potential meso-
dermal progenitor population expressing VEGFR2 (KDR) (up to
2%) consistently developedwithin the CXCR4+cKIT+ population
at day 5. In an attempt to further enrich the endoderm population
from potential KDR+ mesodermal progenitors, the KDR+ cells
were excluded from the day 5 CXCR4+cKIT+ fraction with the
use of fluorescence-activated cell sorting (FACS) (Figure 1B).
When further cultured, the day 5 CXCR4+cKIT+KDR+ cells
generated mostly CD31+ endothelial cells, confirming their
mesodermal potential (Figure S1A available online). The day 5
CXCR4+cKIT+KDR enriched endoderm cell population, with
purity always higher than 95% (97.36% ±1.3% for n = 15 exper-
iments), was then cultured to allow hepatic specification in the
presence of a serum-free hepatic media (described in Experi-
mental Procedures). Immunostainings for the endoderm markerFOXA2; hepatic markers alpha fetoprotein (AFP, the first marker
of hepatic specification), albumin (ALB, a marker indicative of
further hepatic maturation), and HNF4a; epithelial markers cyto-
keratin 18 (CK18, expressed in hepatocytes and progenitor cells)
and cytokeratin 19 (CK19, present in progenitors and cholangio-
cytes); and the endothelial marker CD31 indicated a concomitant
and progressive emergence of hepatic cells with endothelial
cells (Figure S1B). The specification and maturation of hepatic
cells, as well as the generation of endothelial cells, was
confirmed by real-time quantitative PCR (qPCR), with increasing
transcript levels over time for AFP,ALB, a1-antitrypsin (AAT), the
P450 enzymes CYP3a7 and CYP3a4, and also detectable
transcript levels for HNF4a and CD31 (Figure S1C). Decreased
transcript levels for the hepatoblast marker CK19 provided
further evidence for the maturation of the hepatic cells in culture.
Even though hepatic cells express many hepatic markers found
in adult hepatocytes, they also express AFP, indicative of imma-
ture hepatic cells that mostly resemble immature fetal hepato-
blasts rather than mature adult hepatocytes (Figures S1B and
S1C). The identity of the hepatic cells was also supported by
the presence of cytoplasmic glycogen (Figure S1D).
For evaluation of the contribution of the endothelial cell lineage
to these hepatic cultures, flow cytometry analyses for the endo-
thelial markers CD31 and KDR were performed at different
time points (Figures 1C, 1D, and S2A). The percentage of the
KDR+CD31+ endothelial cells (hereafter termed ‘‘K+C+’’) was
the highest at day 12 (Figures 1C and S2B with 2.7% ± 2%).
To confirm their endothelial identity, we purified K+C+ cells
from day 9 hepatic cultures and further cultured them in hepatic
media until day 17. Immunostainings in the dish indicated that all
cells maintained expression of CD31 and KDR and expressed
the typical cytoplasmic endothelial marker von Willebrand factor
(Figure S2C). Moreover, purified K+C+ cells formed the charac-
teristic vascular-like network developed by endothelial cells in a
matrigel assay (Figure S2D).
In addition to the K+C+ endothelial population, the flow
cytometry analyses revealed two major distinct populations:
the KDR+CD31 cells (hereafter termed ‘‘K+C’’) and the
KDRCD31 cells (hereafter termed ‘‘KC’’) (Figures 1C,
1D, S2B, and S2E). Given that the sorted endoderm was origi-
nally negative for KDR, we set out to determine the origin of
the K+C population. Interestingly, daily flow cytometry analysis
combined with immunostaining in the dish from day 7 to day 11
hepatic cultures indicated a hierarchy in the emergence of the
three populations and of the cells expressing AFP and HNF4a.
Expression of the early marker for hepatic endoderm, HNF4a,
is induced as early as day 7, similar to KDR expression (Fig-
ure 1D). KDR staining appeared to be both cytoplasmic and at
the cell membrane (Figure 1D) as seen in Huvec endothelial cells
(Figure S2C). However, AFP expression is initiated after the
emergence of K+C cells and is further increased as the
K+C population expands (Figure 1D). One possibility is that
K+C cells derive from the fusion of KC hepatic cells with
K+C+ endothelial cells (although the endothelial component of
the culture represented by the K+C+ cells is very small at these
early time points). Two different strategies were used to rule out
fusion as a mechanism by which K+C cells are generated. The
first strategy consisted of coculturing the KC cells with K+C+
cells purified from day 9 HES-2-derived hepatic cultures (FiguresCell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc. 749
Figure 1. Concomitant Development of KDR–CD31– Hepatic Cells, KDR+CD31– Prehepatic Cells andKDR+CD31+ Endothelial Cells in hESC-
Derived Hepatic Cultures
(A) hESC hepatic differentiation protocol.
(B) Flow cytometry analyses from day 4 and day 5 (d4 and d5) EBs. Numbers reflect means ± SD for 15 experiments (n = 15) for CXCR4 and cKIT, and n = 3 for
PDGFRa.
(C and D) Flow cytometry analyses (C) and immunostainings (D) from hepatic cultures generated from the plated day 5 CXCR4+cKIT+KDR cells at different time
points (3200).
(E) Relative transcript levels in K+C and KC populations purified from day 12 and 17 hepatic cultures. Gene expressions from day 5 CXCR4+cKIT+KDR
cells (d5 ‘‘End’’) were set to 1, except for ALB expression, for which the day 17 isolated KC cells were set to 1. Data are represented as mean ± SD (n = 4).
See also Figures S1, S2, S3, and S4.
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KDR and CD31 expression at days 11, 13, and 15 of differentia-
tion, looking for the emergence of K+C cells that could be
explained by fusion between the two cell types. Even after
6 days of coculture, no K+C cells developed. Moreover, all
cells expressing KDR coexpressed CD31 (Figure S3B), confirm-
ing the absence of K+C cells in these cocultures. The second
strategy tested whether fusion between KC cells and K+C+
cells can occur as the two cell types develop together (Fig-
ure S3C). Therefore, purified day 5 endoderm cell populations
from the H9-GFP line (constitutively expressing GFP) or from
the H9-DsRed line (constitutively expressing DsRed) were750 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.cultured together, and the origin of the K+C cells was exam-
ined as they arose (from the H9-GFP or H9-DsRed line if there
was no fusion, or from both H9-GFP and H9-DsRed if there
was fusion). These data determined that at day 9 of differentia-
tion, when the K+C population was the largest (for both sets
of endoderm populations), the K+C cells expressed either
GFP or DsRed, but never both. In summary, we provide strong
evidence that cell fusion between K+C+ endothelial cells and
KC hepatic cells is not a mechanism responsible for the
generation of K+C cells. Instead, we propose, based on exper-
iments described below, that they are a hepatic precursor pop-
ulation derived from CXCR4+cKIT+KDR endoderm cells.
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cells were purified at day 9, cytospun, and immunostained for
KDR, FOXA2, AFP, and CK18. All sorted cell populations con-
tained a purity greater than 97% (Figure S4A). The presence of
KDR in K+C cells and its absence in KC cells were
confirmed (Figure S4B). Both populations expressed CK18 and
the endoderm marker FOXA2, even though levels of FOXA2
were much higher in KC cells. However, the hepatic protein
AFP was exclusively expressed in KC cells at this early time
point. Protein expression for these markers was consistent
with the transcript levels analyzed by qPCR in K+C and
KC populations purified at two later time points, day 12 and
day 17 (Figure 1E). Gene-expression levels were compared to
those from the day 5 CXCR4+cKIT+KDR cells (Figure 1E, d5
‘‘End’’). The KDR transcript levels reflected the protein levels
assessed by flow cytometry. The transcript levels of the endo-
derm marker FOXA2 and the hepatic markers AFP and ALB
were higher in KC cells compared to those in K+C cells at
both time points (24-fold for FOXA2, 42.5-fold for AFP, and 10-
fold for ALB at day 17). However, these levels were much higher
in K+C cells than in day 5 CXCR4+cKIT+KDR cells (24.6-fold
for AFP and 150-fold for ALB at day 17), indicating that K+C
cells progressed to an intermediate hepatic fate. In addition,
levels of the ventral endoderm marker GATA4 (Laverriere et al.,
1994) and the epithelial hepatic marker CK18 were similar in
both populations, supporting the hepatic endoderm character
of both populations.
Overall, these data demonstrate the coemergence of three
populations upon hepatic specification of the hESC-derived
endoderm: the KC hepatic cells, the K+C+ endothelial cells,
and the K+C cells that most likely represent a previously un-
characterized prehepatic precursor population.
The K+C– Cells Promote KDR-Mediated Hepatic
Maturation of the K–C– Cells in a Non-Cell-Autonomous
Manner
Given that the K+C and KC cells develop concomitantly, we
next asked whether the K+C cells are supportive in promoting
hepatic specification and maturation of the KC cells. We first
needed to clarify the hepatic fate potential of both KC and
K+C purified populations under defined culture conditions.
We compared each cell population either cultured separately
or upon coculture with a ratio of 50:50 to reflect the proportion
of both populations found in hepatic cultures. K+C and
KC populations were purified at day 9, cultured separately
(Figure S4C) or cocultured (Figure 2A), and their phenotypes
were analyzed at day 17. For tracking the fate of each population
in coculture conditions, K+C cells were purified from the HES-2
cultures, whereas the KC cells were derived from the HES2-
RFP cultures (Figure S4D). Immunostainings indicated that both
populations grown either separately (Figure S4C) or cocultured
(Figure 2A) did not modify their phenotype. KCRFP+ cells
maintained expression for AFP, EpCAM, and CK18 in both
separate cultures (Figure S4C) and cocultures (Figure 2A).
K+CRFP cells maintained expression of CK18, whereas
expression of EpCAM and AFP proteins was still not detectable
in coculture conditions (Figure 2A), even though low levels of
AFP transcriptswere detected at day 17 in these cells (Figure 1E).
Immunostaining for FOXA2 in cocultures confirmed high levels ofexpression in KC cells and lower levels in K+C, as found
previously by qPCR (Figure 2A). These stainings indicated that
day 9 K+C cells do not specify to a hepatic fate following
further coculture with the day 9 KC cells in a monolayer cul-
ture system. The monolayer culture is therefore ideal for deter-
mining whether the K+C cells improve the hepatic fate of the
KC cells without the potential complication of the K+C pop-
ulation generating cell-autonomously hepatic cells, as this does
not occur in monolayer culture.
Indeed, the ratio between the transcript levels found in cocul-
tures (K+C with KC) and KC single cultures indicated
that K+C cells highly induced AFP and ALB levels in cocul-
tured KC cells at day 13 (11.5 ± 1.84-fold and 40.3 ±
21.12-fold, respectively), as well as at day 17 (5.3 ± 3.27-fold
and 35 ± 12.6-fold, respectively) (Figure 2B). Because of the
concomitant development of the endothelial K+C+ cells with
the KC cells in this study and our previous work indicating
that murine endothelial cells constitute a niche for the murine
endoderm to specify to a hepatic fate (Han et al., 2011), the
ability of the K+C+ cells to improve hepatic specification of
the KC cells was also tested. Endothelial K+C+ cells were
purified from day 9 cultures and further expanded in culture
for 7 days prior to coculture with KC cells, with a cell ratio
of 5% K+C+ cells and 95% KC cells to mimic the proportion
observed in hepatic cultures. Because this ratio was very small,
we also tested a combination of 25% of K+C+ cells with 75%
of KC cells (data not shown). With both cell ratios, gene-
expression analyses showed no change in AFP and ALB
transcripts following coculture of the KC cells with the endo-
thelial K+C+ cells (Figure 2B). Thus, in contrast to what was
shown to be the case in the mouse ESC system, here the sup-
portive effect on KC hepatic specification was not provided
by the K+C+ endothelial cells, but instead was provided by the
K+C cells. However, both supportive cell types, endothelial
cells in the mouse system and K+C cells in the human system,
express KDR, which we hypothesized may be required for the
supportive effects.
To determine whether KDR expressed on K+C cells medi-
ates the hepatic specification and maturation of KC cells,
we cultured the day 5 CXCR4+cKIT+KDR endoderm-enriched
population in monolayer in the presence of either a KDR-inhibi-
tory antibody or the small molecule SU5416, a VEGFR2 kinase
inhibitor III (Figure 2C). By day 17, blocking KDR function did
not affect AFP transcript levels but dramatically reduced levels
of ALB transcripts (45-fold with the KDR antibody and 75-fold
with SU5416), reaching the low levels found in day 12 cultures
in the absence of KDR inhibition (Figure 2C). The KDR-inhibitory
antibody did not significantly alter the proportion of the three
K+C+, K+C, and KC populations (data not shown). To
analyze the specificity of the inhibitory function of the antibody
and the SU5416 on KDR expressed on K+C cells, the KDR anti-
body and SU5416 were tested on cells that don’t express KDR
(the KC cells cultured alone), on KC cells cocultured
with either cells that express KDR but that are not effective
(the K+C+ endothelial cells, Figure S4E), or with the effective
K+C cells (Figure 2D). As illustrated in Figure 2B, KC cells
were purified from day 9 cultures and grown in the presence or
absence of KDR antibody or SU5416 alone or cocultured with
the purified day 9 K+C (Figure 2D) or day 9 K+C+ cellsCell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc. 751
Figure 2. The K+C– Prehepatic Cells Are Supportive Cells for the Hepatic Maturation of the K–C– Hepatic Cells through KDR
(A) Immunostainings of day 17 cocultures between the day 9 purified K+C and day 9 purified KC cells (3200).
(B) Illustration of the comparison strategy between KC cultured alone with either the coculture KC and K+C (50:50) or with the coculture KC and K+C+
(95:5). Graphs represent fold change for transcript levels from the coculture (KC and K+C or KC and K+C+) versus KC cells cultured alone and
harvested at day 13 and day 17 (n = 3 except for AFP and ALB expression from day 17 K+C and KC versus KC for which n = 10).
(C andD) Relative transcript levels in hepatic cultures generated fromday 5CXCR4+cKIT+KDR cells (C) or fromday 9 purified KC cells cultured alone (purple
columns, D) or cocultured with day 9 purified K+C (green columns, D) in the presence or absence of a KDR-inhibitory antibody (C and D, left panels) or a small-
molecule SU5416 (C and D, right panels). KDR antibody or SU5416 were added to the culture media every 2 days. Transcript levels were set to 1 for the day 5
CXCR4+cKIT+KDR cell (d5) group (C, left panels), for the day 9 cultures in the presence of DMSO (C, right panels), for the day 13 KC single cultures in the
presence of IgG isotype control (D, left panels), or for the day 13 KC single cultures in the presence of DMSO (D, right panels) (n = 4 for KDR antibody inhibitor
and the IgG isotype control, and n = 3 for SU5416 and DMSO control).
(B–D) Data are represented as mean ± SD. AFP and ALB levels were not significantly different and very similar in the presence of IgG isotype control for KDR or
with media alone (data not shown).
See also Figure S4.
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VEGFR2/KDR Identifies a Hepatic Progenitor(Figure S4E). As expected, AFP and ALB levels in KC cells
alone increased from day 13 to day 17 and were not altered by
the presence of the KDR-inhibitory antibody nor by SU5416 (Fig-
ures 2D and S4E, purple columns). Cocultures of KC cells
with K+C+ cells (Figure S4E, coculture blue columns) did not
improve these levels, confirming the nonsupportive role of
K+C+ cells on KC cell hepatic fate. In contrast, cocultures
of KC cells with K+C cells (Figure 2D, coculture green
columns) induced AFP and ALB levels at both day 13 and day752 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.17 time points. KDR-inhibitory antibody or SU5416 in cocultures
abrogated theALB increase induced by the coculture seen at the
later time point, day 17 (a 76-fold and 146-fold decrease, respec-
tively), indicating that KDR expressed on K+C cells mostly con-
trols hepatic maturation (ALB levels), but not specification (AFP
levels), of the KC cells.
Our findings demonstrate that KCmaturation is supported
in a non-cell-autonomous manner, dependent on active KDR
signaling in the K+C population.
Figure 3. The hESC-Derived K+C– Cells Are Hepatic Progenitors
(A) Fold change for transcript levels of the ratio of three-dimensional relative to two-dimensional cultures (3D/2D) from day 9 purified K+C or KC populations,
analyzed at day 17 (n = 3).
(B) Relative transcript levels from purified day 9 K+C and KC cells grown either in 2D or in 3D and analyzed at day 17 (n = 4). AFP and ALB levels were set to 1
for KC cells.
(C) Immunocytostainings of the cytospun day 9 purified K+C and KC cells grown for 4 days either in 3D or in 2D (3200). One representative experiment out of
two is shown.
(D) Relative transcript levels in day 9 K+C and KC cells grown in 3D in the presence or absence of KDR-inhibitory antibody and analyzed at day 17 (n = 3).
Transcript levels were set to 1 for K+C cells in the absence of KDR antibody (the controls used media alone).
(E) Flow cytometry analyses from 15- to 24-week-old human fetal liver preparations (n = 4).
(F) Immunocytostainings of dissociated and cytospun 21- to 22-week-old human fetal livers (3200).
(A, B, D, and E) Data are represented as mean ± SD.
See also Figure S5.
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In addition to the supportive function of the K+C cells, we next
examined whether the K+C cells represent a pool of progeni-
tors for hepatic cells. Although this was not seen in monolayer
(2D) cultures, in an attempt to induce hepatic specification of
the K+C cells, purified day 9 populations were cultured in 3D
structures (3D aggregates) (Figure 3), which often favor hepatic
cell lineage maturation (Han et al., 2012). Day 9 K+C cells
formed large and compact aggregates, whereas the aggregates
from day 9 KC cells remained small (Figure S5A). Hepatic
specification and maturation in 3D were dramatically inducedby day 17 in both populations compared to those in 2D, indicated
by increased levels of AFP (98 ± 2.47-fold in K+C cells; 87 ±
26.9-fold in KC cells) and ALB (68 ± 40.25-fold in K+C cells;
1,200 ± 186-fold in KC cells) (Figure 3A). Analyses of AFP and
ALB transcripts at day 17 showed higher levels of AFP and
similar levels of ALB in K+C 3D cultures compared to the he-
patic KC 2D cultures, indicating hepatic specification of the
K+C cells in 3D (Figure 3B). Hepatic specification of the
K+C cells was confirmed at the AFP protein level, as most of
the K+C cells cultured in 3D expressed AFP (Figures 3C and
S5B, 3D cultures). In 2D cultures, AFP protein was neverCell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc. 753
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some KC cells (Figures 3C and S5B, 2D cultures). AFP
expression was dramatically increased in KC cells cultured
in 3D, in that all cells expressed AFP (Figures 3C and S5B, 3D
cultures). 3D cultures not only induced hepatic fate of the
K+C progenitors but also improved hepatic maturation of the
KC hepatic cells. Although numerous studies using human
pluripotent stem cells have shown efficient hepatic differentia-
tion in monolayer culture, none investigated the fate of progeni-
tors (endoderm and hepatic progenitors) following cell purifica-
tion prior to subsequent culture, experimental conditions that
greatly impact the cell’s capacity to specify efficiently in mono-
layer. It was thus not surprising that 3D culture was required
for specification and maturation of the purified K+C progeni-
tors. Importantly, we tested whether the hepatic fate of K+C
cells in aggregates was mediated through KDR. Purified day 9
K+C cells, as well as the day 9 KC cells, were aggregated
in the absence and presence of KDR-inhibitory antibody until
day 17. As expected, KDR inhibition did not affect AFP and
ALB levels in KC aggregates, but significantly reduced AFP
(2.33-fold) and ALB (4-fold) levels in K+C 3D cultures
(Figure 3D).
This data further confirmed the specificity of the KDR-inhibi-
tory antibody and indicated that hepatic specification and matu-
ration induced by the 3D cultures of K+C cells is mediated
through KDR in a cell-autonomous manner. Furthermore, these
results demonstrate the hepatic potential of the K+C cells in
a 3D culture context that is likely to better recapitulate the cell-
cell interactions that occur during liver development.
Identification of a Similar K+C–Cell Population inHuman
Fetal Livers
Human fetal livers from 15- to 24-week-old fetuses were disso-
ciated into single-cell suspensions and analyzed via flow cytom-
etry for KDR and CD31 expression (Figure 3E). For exclusion of
the blood cells that constitute the majority of the fetal liver
(Migliaccio et al., 1986), cells were immunostained with the
leukocyte marker CD45, as well as the erythroid marker
CD235a. The negative cells for both hematopoietic markers
(about 16% of total cells) were gated and analyzed for KDR
and CD31 expression (Figure 3E). Even though the fetal livers
examined were staged beyond the developmental stages
analyzed in hESC cultures, a substantial cell population of the
nonhematopoietic cells (12% ± 5.8%) was identified as K+C,
a phenotype reminiscent of the K+C hESC-derived hepatic
progenitors. A fraction of the K+C cells expressed the known
marker for human fetal hepatic progenitor, CDH1 (Terrace et al.,
2007), as assessed by flow cytometry (10.6% ± 8%), and low
levels of ALB (Schmelzer et al., 2007), assessed by identification
of KDR+ALB+ cells following costaining on cytospun cell prep-
aration (Figures 3F, arrows, and S5C). CDH1 was found to be
expressed in both the K+C and KC fractions. This was
not surprising, given that K+C cells most likely constitute
only a subset of the hepatic progenitor pool, the other progen-
itors being KC. Many KDR+ cells coexpressed CD31, mostly
defining the endothelial cell lineage (Figure 3F, area with an
asterisk). However, some KDR+ cells excluded CD31 expres-
sion (Figure 3F, arrows), supporting the existence of the
K+C population detected by flow cytometry, which may repre-754 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.sent the KDR+ALBlo cells. To confirm the immunostaining of cy-
tospun liver cell suspensions, sections of 22-week-old fetal
livers were also immunostained for the same markers and
examined with a confocal microscope using images of
0.25 mm depth (Figures S5D–S5F). Arrows indicate KDR+ cells
coexpressing the hepatic marker ALB (Figures S5D and S5F),
as well as some KDR+ cells that exclude the endothelial marker
CD31 (Figures S5E and S5F) and hence may represent the he-
patic progenitors.
Altogether, analyses of early human fetal livers identified a
similar K+C cell population expressingmarkers for hepatic pro-
genitors (CDH1 and low levels of ALB), suggesting that some
KDR+ cells represent an intermediate hepatic progenitor in
human fetal livers, as found in hESC differentiation cultures.
The hESC-Derived K+C– Hepatic Progenitors Support
the HCV Life Cycle following Hepatic Specification and
Maturation
To functionally evaluate hepatic progenitor cells, we tested their
ability to support infection and replication of HCV, which are fea-
tures unique to bona fide hepatocytes (Shulla and Randall,
2012). We determined the ability of the K+C cells to support
HCV infection either in 2D cultures, which maintain their progen-
itor characteristics, or in 3D cultures following hepatic specifica-
tion and maturation. For comparison, the hepatic functionality of
the counterpart KC hepatic cells, cultured either in 2D or 3D,
as well as the day 13 hepatic differentiation cultures (Hep-hESC),
were analyzed similarly (Figure 4A). Cells were challenged with
infectious HCV particles that are capable of both entering and
replicating in permissive host cells (Figures 4A–4C). Quantifica-
tion of viral RNA replication over time by qPCR in cells (Figure 4B)
or secreted in cell supernatants (Figure 4C) following infection re-
vealed that K+C cells cultured in 2D were poorly infected,
whereas K+C cells cultured in 3D supported efficient HCV
RNA replication (Figure 4B, 25-fold induction; Figure 4C, 51-
fold induction) to levels equivalent to those observed in hepatic
KC cells (in either 2D or 3D) or in Hep-hESC. The increase
in signal was dependent on authentic HCV RNA replication
mechanisms, because the HCV RNA polymerase inhibitor 20C-
methyl-adenosine (20CMA, Figures 4B and 4C) prevented RNA
amplification over time. This replication was extremely efficient;
RNA levels were comparable to those observed in parallel infec-
tions of human hepatoma-derived Huh-7.5 cells (Figures 4B and
4C), which are more susceptible to HCV infection than any other
known cell line. Thus, an infection that approaches the levels
observed in Huh-7.5 cells should be considered compelling.
Furthermore, the HCV RNA secreted by K+C cells (in 3D
only), KC cells (in either 2D or 3D), or Hep-hESC was vali-
dated to represent newly produced infectious virus by titering
on naive Huh-7.5 cells (Figure 4D, tissue culture infectious doses
50% per ml [TCID50/ml]). Indeed, levels of infectious-virus
release from 3D K+C cells (3D only), KC cells (in either 2D
or 3D), or Hep-hESC were similar and approaching those in
Huh-7.5 cells.
Thus Hep-hESC, KC hepatic cells, and the K+C cells that
are further specified and matured in 3D culture conditions all
support the entire HCV life cycle nearly as efficiently as the
best-case Huh-7.5 cells. Therefore, the K+C cells are true pro-
genitors that derive functional hepatic cells.
Figure 4. K+C–Hepatic Progenitors Support HCV Infection following
Specification and Maturation
(A) Illustration of theHCV infection protocol. Cell populations infectedwithHCV
were the day 9 purified K+C or KC cells further cultured in 2D or 3D for 4
more days (until day 13), the day 13 hepatic cultures (Hep-hESC that includes
both KC and K+C cells), and the highly HCV-permissive Huh7.5 cells. For
the 3D cultures, floating aggregates were plated onto matrigel the day before
infection. All cell populations were infected at day 13 of differentiation.
(B) Intracellular HCV RNAwas quantified by qPCR at the indicated time points,
either in the absence (blue columns) or presence (gray columns) of 20CMA.
(C) HCV RNA released from supernatants of the above infections was quan-
tified by qPCR.
(D) Infectious virus in these supernatants was quantified with a limiting dilution
assayonHuh7.5cells and representedby theTCID50/ml. 20CMAcontrols for the
presence of input HCV RNA derived from particles introduced during infection.
For (B–D), values are normalized to Huh7.5 readings at 48 hr post infection
(h.p.i.) and represent means ± SD of two independent experiments, each
performed in triplicate. **p < 0.01, ***p < 0.001 (Mann-Whitney test).
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VEGFR2/KDR Identifies a Hepatic ProgenitorKDR+ Progenitors Contribute to Early Hepatic
Endoderm and Hepatoblast Development In Vivo
In order to provide in vivo evidence for the existence of a KDR-
expressing hepatic progenitor, mouse embryos from embryonicday 8.0 (E8.0) (prior to hepatic specification), E8.5 (hepatic endo-
derm stage), E9.5 (liver bud stage), and E13.5 (fetal livers) were
examined for expression of KDR and the endoderm marker
FOXA2 by immunostaining. Few KDR+FOXA2+ cells were de-
tected in foregut endoderm andwere only found in E8.0 embryos
prior to hepatic specification (Figure 5A, arrows indicating two
KDR+FOXA2+ cells). To demonstrate the in vivo contribution of
KDR+FOXA2+ endoderm cells to the hepatic lineage, we used
a Kdr lineage-tracing mousemodel. This mousemodel is a cross
between the heterozygous Kdr-Cre mouse, in which the Cre re-
combinase gene was knocked into the Kdr locus (Motoike et al.,
2003), and the homozygous reporter enhanced YFP mouse, in
which YFP is ubiquitously expressed under the Rosa26 pro-
moter, after Cre recombinase excises theSTOP cassette flanked
by LoxP sites (Srinivas et al., 2001). This well-established and
validated model has been used extensively by other groups to
track early progenitors for hematopoietic cells (Lugus et al.,
2009) and endothelial cells (Coveney et al., 2008; Lavine et al.,
2006; White et al., 2007). The Kdr-Cre line is a Cre knockin into
the first exon of the Kdr gene, faithfully expressing KDR, as
was validated after crossing with the Rosa26-LoxpSTOPLoxpLacZ
line (Motoike et al., 2003). The resulting offspring include 50% of
the mice carrying the lineage tracer (hereafter YFPpos mice) and
50% of the mice without YFP+ cells, used as a negative control
(hereafter YFPneg mice). The YFPpos mice allow tracking of not
only cells expressing KDR, but also descendant cells that subse-
quently downregulate KDR expression.
To evaluate the KDR cell-lineage tracing efficiency in the
YFPpos mice, trunks of E10.5 embryos (whole embryos with the
exclusion of limbs, head, and tail) and E13.5 fetal livers were
dissociated and analyzed by flow cytometry for KDR expression
and YFP fluorescence (Figure S6A). Data pooled from either 11
E10.5 embryos or 36 E13.5 fetal livers indicated that 57.3% ±
8.6% or 40% ± 15.1% of KDR+ cells coexpressed YFP, respec-
tively (Figure S6A). The progeny of KDR+ cells found at these
early time points include endothelial cells and the primitive
hematopoietic cells that represent about 90% of the cells in
E13.5 fetal livers. To specifically assess the lineage-tracing effi-
ciency for tracking endothelial cells, we performed similar flow
cytometry analyses using the endothelial marker CD31 (Fig-
ure S6B). We found that 79.4% ± 10.9% (n = 11, E10.5
embryos) and 72.8% ± 9.5% (n = 36, E13.5 fetal livers) of
CD31+ cells costained with YFP.
Next,weutilized theYFPposmice to investigate theexistenceof
YFP+ progeny in the hepatocytic lineage. The presence of single
YFP+ cells was detected in two out of seven embryos as early as
E8.5 in the foregut hepatic endoderm, as indicated by single cells
coexpressing YFP and the endodermmarker FOXA2 (Figures 5B,
arrow, and S6C). However, this may be a minimal estimate,
because cells may have been missed due to technical issues
concerning the fragility of consecutive sections of the foregut
endoderm, which made it very challenging to screen the entire
foregut of each embryo. One day later, in E9.5 embryos, many
YFP+ cells coexpressing FOXA2 were found in the developing
liver bud (Figures 5C, arrows, and S6D). The identity of the liver
budwas confirmed by costaining for FOXA2 and AFP on succes-
sive sections (Figure 5D, top panel), and the identity of the YFP
hepatoblasts was confirmed with a costaining for AFP and YFP
(Figure 5D, bottom panel, arrows). The contribution of theCell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc. 755
Figure 5. KDR+ Progenitors Contribute to the Development of Hepatic Endoderm and Fetal Hepatoblasts during Mouse Embryogenesis
(A) Immunostaining of E8.0 foregut endoderm sections from YFPpos mice (3100 for the upper panel;3200 for the four other panels that are the close-up pictures
of the upper panel). FG, foregut diverticulum; NC, notochord; NE, neuroepithelium.
(B) Immunostaining of E8.5 foregut endoderm sections from YFPpos mice. The upper left panel represents a low magnification view (3100), whereas the three
other panels are close-up pictures of the framed field (3200).
(C and D) Immunostaining of E9.5 liver bud sections from YFPpos mice (3200). Insets represent close-up pictures.
(E) Graphs indicate the means ± SD of the percentages of YFP+EpCAM+ cells over the whole EpCAM+ cell population or the percentage of YFP+DLK+ cells over
the whole DLK+ cell population obtained by flow cytometry analyses from 11 trunks of E10.5 embryos and 36 E13.5 fetal livers.
See also Figures S6 and S7.
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VEGFR2/KDR Identifies a Hepatic ProgenitorKDR+ progenitor cells to the hepatoblast population was quanti-
fied in trunks of E10.5 embryos and E13.5 fetal livers by flow
cytometry for YFP and two specific markers for hepatoblasts,
delta-like 1 homolog (DLK)/Pref-1 and the epithelial cell adhesion
molecule (EpCAM). DLK is strongly and specifically expressed
in hepatoblasts from E10.5 to E14.5 embryos (Tanimizu et al.,
2003). Similarly, EpCAM is a specific marker for endoderm de-
rivatives in E9.5 embryos, including hepatoblasts of the liver
bud (Sherwood et al., 2007), and is also expressed homoge-
nously in all hepatoblasts until E14.5 (Tanaka et al., 2009).
Flow cytometry analyses of dissociated E10.5 trunks (from 11
embryos) and E13.5 fetal livers (from 36 livers) indicated that
the percentages of cells positive for EpCAM or DLK coexpress-756 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.ing YFP were similar (15% in E10.5 trunks and 40% in E13.5
fetal livers, Figures 5E and S6E). The identity of the YFP+ hep-
atoblasts was confirmed by coimmunostaining for YFP and
AFP on sections (Figures S7A, arrows, and S7B) from E10.5
embryos and E13.5 fetal livers. Percentages of hepatoblasts
in E13.5 fetal livers ranged between 3% and 4% of the whole
liver cell population based on DLK and EpCAM expression
and were consistent with previous studies using the same
markers, as well as the hepatoblast markers Liv-2 and E-cad-
herin (Nierhoff et al., 2005; Tanaka et al., 2009; Tanimizu
et al., 2003). It is noteworthy that all fetal livers analyzed
(from n = 36 embryos) were consistently composed of a large
population of YFP+ hepatoblasts ranging from 30% to 50%
Figure 6. KDR+ Progenitors Contribute to the Development of Adult
Hepatocytes and Cholangiocytes
(A and B) Immunostaining on liver sections of 5-week-old YFPpos mice (3200).
See also Figure S7.
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VEGFR2/KDR Identifies a Hepatic Progenitorof the total hepatoblast population, indicating that the contribu-
tion of a KDR+ progenitor to hepatoblast development is not a
random event due to leaky Cre expression but rather occurs
consistently and robustly in all embryos.
Altogether, analyses of fetal liver development from the E8.0
hepatic endoderm to the E13.5 fetal liver demonstrated a pro-
gressive and robust contribution in all embryos analyzed of the
KDR+YFP+ progenitors to hepatoblast development, including
up to 50% of the hepatoblast population at E13.5. Given that
the tracing of endothelial cells showed efficiency for Cre at
approximately 75%, this number probably represents an under-
estimate of the true contribution of KDR+ progenitor cells to
hepatoblasts.
KDR+ Progenitors Contribute to Adult Hepatocyte and
Cholangiocyte Development In Vivo
Since the hepatoblast represents a common progenitor for the
adult hepatocyte and cholangiocyte, we investigated whether
the KDR+ cell-derived YFP+ hepatoblasts found in fetal livers
gave rise to adult YFP+ hepatocytes and YFP+ cholangiocytes(Figure 6). Immunostainings of livers from adult YFPpos mice re-
vealed the presence of a large population of YFP+ hepatocytes
easily recognizable by their cuboidal shape (Figures 6A and
S7C). All YFP+ hepatocytes coexpressed hepatocyte markers
including HNF4a; dipeptidyl peptidase-4 (DPP4), which marks
the bile canaliculi at the membrane of hepatocytes; or ALB (Fig-
ures 6A, S7C, and S7D). In contrast to the robust contribution of
KDR+ progenitors to fetal hepatoblast development, the per-
centage of YFP+ hepatocytes in adult mice varies from mouse
to mouse and from lobe to lobe within the same mouse between
1%and40%, as shown in Figure S7E. Careful examination of
the distribution of YFP hepatocytes among many adult livers did
not reveal any specific preferential location in pericentral or peri-
portal regions. Some YFP+ cells also marked cholangiocytes
that were identified by expression for CK19 and SOX9 (Antoniou
et al., 2009) (Figures 6B, arrows, and S7D). This variable contri-
bution suggests that adult YFP+ hepatocytes and YFP+ cholan-
giocytes are replaced over time after birth from YFP progenitor
cells. As expected, most of the endothelial cells were also YFP+
in adult livers (Figure S7F). The variability in detecting endothelial
cells with YFP staining on sections in adult liver was solely due to
the level of exposure used. Hepatocytes are such large cells in
comparison to the very thin endothelial cells that it was techni-
cally difficult to visualize both of them with the same exposure.
When the exposure is increased, it is obvious that most of the
endothelial cells also stain positive for YFP.
Altogether, the KDR lineage-tracing study provides in vivo
evidence for the existence of a KDR+ hepatic progenitor that
contributes robustly to the development of a large subset of fetal
hepatoblasts that in turn differentiate into adult hepatocytes and
cholangiocytes.
DISCUSSION
Hepatocyte transplantation for the treatment of liver diseases
has been proposed as a bridge for whole-organ transplantation,
because there is a severe shortage of liver donors. The field of
pluripotent stem cell differentiation has the potential to provide
a ready and unlimited source for transplantable hepatocytes.
The goal of this study was to uncover the early cellular events
andmechanisms that support the development of hESC-derived
hepatic cells. This study revealed an early hepatic progenitor
defined as a cell expressing KDR that constitutes a pool of
hepatic progenitors and supportive cells for the committed
hepatic cells. The present study reveals that KDR expression un-
expectedly marks an endoderm lineage progenitor which is a he-
patic progenitor.
The K+C human hepatic progenitors defined in this study
share some characteristics with previously described hepato-
cyte progenitors from human fetal livers. Multiple markers have
been utilized for isolating human fetal progenitors, reflecting in
part the different ages of the fetal livers analyzed. In the earliest
stages (before 10 weeks), most studies describe bipotent liver
progenitors that express markers such as CD117, CD34, and
CD90 (Nava et al., 2005; Nowak et al., 2005; Nyamath et al.,
2007). However, human hepatoblasts with classic hepatobiliary
phenotype, characterized by the expression of EpCAM, CK8/
18, AFP, ALB, and CK19 were isolated from the livers at a later
stage (Mahieu-Caputo et al., 2004; Schmelzer et al., 2006). TheCell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc. 757
Figure 7. Identification and Function of the
KDR Hepatic Progenitor Using the In Vitro
hESC System and an In Vivo KDR/YFP
Lineage-Tracing Mouse Model
(A) The in vitro hESC system.
(B) An in vivo KDR/YFP lineage-tracing mouse
model.
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VEGFR2/KDR Identifies a Hepatic ProgenitorK+C progenitor cells established in this study most likely repre-
sent an intermediate hepatic progenitor that expresses CK18 but
is negative for AFP, ALB, and EpCAM in vitro. We were able to
detect K+C cells in the developing human fetal liver. The
relatively low percentage of K+C cells in fetal livers (12% ±
5.8% after exclusion of blood cells) compared to the higher per-
centage found in the hESC differentiation cultures (20% to 65%)
is perhaps due to the fact that the K+C cells develop earlier
(before 15 weeks of gestation) and transiently in the fetal liver.
Studies of liver development in mice have helped determine
the timing of the emergence of liver progenitor cells. To date,
all known hepatic progenitor markers defined in the literature
identify hepatoblasts (LIV2, DLK/Pref-1, Nope, E-cadherin,
cMET, and EpCAM) (Nierhoff et al., 2007; Nitou et al., 2002; Su-
zuki et al., 2002; Tanaka et al., 2009; Tanimizu et al., 2003) or
stem cell-like cells as emerging when the fetal hepatoblast de-
termines either a hepatocytic or cholangiocytic fate. Stem cell-
like cells are localized in the developing portal track in E14.5–
E16.5 embryos and are identified by expression of SOX9
(Furuyama et al., 2011). Stem cell-like cells are also found as
dormant cells in adult livers in the portal track area, and they
contribute to liver regeneration in the case of severe injury
(SOX9, FOXL1, EpCAM, and LGR5) (Dorrell et al., 2011; Fur-
uyama et al., 2011; Huch et al., 2013; Okabe et al., 2009; Sack-
ett et al., 2009). In contrast to these studies, the previously un-
reported KDR+ hepatic progenitor uncovered in the present
study appears in the endoderm before the hepatoblast stage,
characterizing it as a progenitor for the hepatoblast.
We provide evidence that the K+C cells are not only hepatic
progenitors but also support the maturation of KC hepatic
cells, mediated indirectly through the KDR receptor, and that
this supportive effect is not promoted by the other hepatic
cell niche component, the K+C+ endothelial cells. This was
intriguing, in that several groups including ours have shown
the supportive function of endothelial cells in promoting hepatic
specification and expansion of the hepatic endoderm in early
mouse liver development (Han et al., 2011; Matsumoto et al.,758 Cell Stem Cell 12, 748–760, June 6, 2013 ª2013 Elsevier Inc.2001) and in promoting mouse liver
regeneration (Ding et al., 2010). The
discrepancy of the role of endothelial
cells in liver development between the
mouse and human systems may be due
to the different timing of appearance of
the supportive progenitor cells in both
species. In the mouse, the KDR progen-
itors are transient cells found in the fore-
gut endoderm no later than E8.0, sug-
gesting a possible role for the
progenitors in hepatic specification of
endoderm, but most likely notin hepatic endoderm expansion, as shown previously for endo-
thelial cells. In contrast, in hESC hepatic differentiation cultures,
the KDR progenitors develop prior to endothelial cells and in
parallel to hepatic cells, and they remain for days. Their persis-
tent concomitant presence with the developing hepatic cells
may explain their critical role in hepatic specification and matu-
ration, compared to endothelial cells. Nevertheless, both cell
types, progenitors and endothelial cells, have a common
feature; they both express KDR. Absence of KDR correlated
with a lack of endothelial cells in Kdr/ mice led to reduced
ALB transcript levels in liver bud transplants (Matsumoto
et al., 2001). Similarly, inhibition of KDR expressed on hepatic
progenitors in hESC hepatic cultures blocked ALB transcript in-
duction. Even though the supportive cells are different in the
two systems, they seem to both act through the same KDR re-
ceptor to regulate hepatic maturation.
In summary, using the hESC system, we define a hepatic niche
in which the KC committed hepatic cells (AFP+ALB+)
develop concomitantly with the K+C hepatic progenitors
(AFPALB) (Figure 7A). The K+C progenitors can differen-
tiate through a KDR-mediated mechanism into hepatic cells
(KDR+AFP+) that are functional, given that they support HCV
pathogenesis and presumably transition by downregulating
KDR to generate the typical KCAFP+ hepatic cells. The
K+C progenitors are also supportive cells for the KC
committed hepatic cells, improving their maturation through a
KDR-mediated mechanism. The identity and function of the
K+C cell as a hepatic progenitor is conserved in the mouse.
In the mouse embryo, KDR+ cells are localized in the endoderm
in early E8.0 embryos prior to hepatic specification and further
specify to hepatoblasts as KDR expression is downregulated.
KDR progenitor-derived hepatoblasts in turn give rise to a subset
of adult hepatocytes and cholangiocytes (Figure 7B).Wedemon-
strated in this study that KDR, originally defined as amesodermal
marker and functional receptor for vascular and hematopoietic
proper development, also marks hepatic endoderm progenitors
and functions to instruct early human liver development.
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hESC Hepatic Differentiation
The day prior to differentiation, hESCs were harvested using accutase and
passaged onmatrigel to deplete the mouse embryonic fibroblasts (Invitrogen).
At day 0 of differentiation, dissociated hESCs were cultured in low cluster
plates (Costar) to allow EB formation in serum-free differentiation (SFD) media
as previously described (Han et al., 2011), supplemented with BMP4 (3 ng/ml,
R&D Systems). At day 1 the medium was changed to SFD media supple-
mented with Activin A (100 ng/ml, R&D Systems), basic FGF (bFGF,
2.5 ng/ml, R&D Systems), and BMP4 (0.5 ng/ml, R&D Systems). At day 4,
the medium was changed to the SFD media supplemented with Activin A
(100 ng/ml), bFGF (2.5 ng/ml), and vascular endothelial growth factor (VEGF,
10 ng/ml, R&D Systems). The day 5 EBs were dissociated, and the CXCR4+
cKit+KDR cells were isolated by FACS and subsequently plated on
gelatin-coated dishes (50,000 cells per well of a 48-well plate) in hepatic media
as previously described (Han et al., 2011). Inhibition of KDR was performed by
adding the KDR-neutralizing antibody (40 ng/ml; R&D Systems) or SU5416
(5 mM; Millipore) every other day from the day 6-plated CXCR4+cKIT+KDR
cells or from the day 10-plated K+C, KC, and K+C+ sorted cells. The iso-
type immunoglobulin G (IgG, 40ng/ml; Jackson ImmunoResearch) or dimethyl
sulfoxide (DMSO, 5 mM; Sigma-Aldrich) were added in the media as controls.
Human Fetal Liver Dissociation
Fetal liver specimens between 15 and 24 weeks’ gestation were obtained at
the Mount Sinai Medical Center. This study has been approved by the Mount
Sinai institutional review board office as non-human-subject research.
Mice
Kdr-Cre, Rosa26-EYFP mice were obtained by crossing the Kdr-Cre mice
(Motoike et al., 2003) with Rosa26R-EYFP mice (Srinivas et al., 2001) for visu-
alization of KDR lineage-tracing cells. The use of mouse models in these ex-
periments received Institutional Animal Care and Use Committee approval.
Statistical Analysis
Results are expressed as mean ± SD. For each group, at least three ex-
periments were analyzed, and different groups were compared using the
t test analysis. p < .05 was considered statistically significant; *, p < .05;
**, p < .01; and ***, p < .001. Additional experimental procedures are listed in
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.04.026.
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